Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Cost of Drug Development Reduced Thanks to New Technology

Published: Friday, January 18, 2013
Last Updated: Friday, January 18, 2013
Bookmark and Share
De Montfort University (DMU) has come together with Ithaka Life Sciences Ltd to market new technology designed to speed up and reduce the cost of the development of new drugs and medicines.

A leading expert at DMU, Professor Bob Chaudhuri, has invented the technology which will provide useful new products and services, based on a set of proteins, named cytochrome P450s (CYPs).

CYPs are found in the human liver and are mostly responsible for the metabolism of drugs in people. These proteins are commercially available for use by companies involved in the discovery of new drugs, but are inconvenient to use as they must be transported and stored at temperatures as low as minus 80 degrees Celsius.

This new technology allows for CYPs to be shipped and handled at room temperature, eliminating the need for a cold chain. This will reduce the cost and make their use in testing new drugs much quicker and easier.

Together, DMU and Ithaka have established a new company which will be called CYP Design Ltd (CDL).

Professor Chaudhuri said: “The development of new drugs can be very time-consuming and costly. It can take up to 14 years from the initial idea and cost hundreds of millions of pounds. Thousands of potential new drugs are tested initially for every one successfully brought to market.

“Early drug discovery work has to identify new chemical compounds which are potentially useful without being toxic to humans. Current testing methodologies do not address the problem as these model systems often react differently than humans to new chemicals.

“My group’s development is designed to provide the proteins that are needed for this work in a cost effective and convenient format.

DMU has licensed this new technology to CDL which is now seeking to bring the new products to market. Ithaka has worked closely with Professor Chaudhuri to set up CDL and is leading the implementation of the business strategy through Dr Bill Primrose as CEO and Dr Paul Rodgers as Chairman.

Dr Bill Primrose said: “We’re delighted to be working with DMU and believe that the technology that Professor Chaudhuri has been developing can have a significant impact on the timescales and costs involved in the early stages of drug discovery.

“CYPs are currently transported on dry ice, at around minus 80 degrees Celsius, and are stored as cold as possible in the customer’s laboratory until they are needed.

“His new technology eliminates the need for a cold chain making it easier to manufacture and ship the proteins, and making them much more convenient for the customer to use.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
Bacterial Genes Boost Current in Human Cells
Borrowing and tweaking bacterial genes to enhance electrical activity might treat heart, nervous system injury.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
Untangling a Cause of Memory Loss in Neurodegenerative Diseases
The mouse study identifies a possible therapeutic target for a family of disorders.
New Pathway for COPD Biomarker Development
A study from Philip Morris International has highlighted multi-lipid profiling as a potential new pathway for COPD biomarker development.
Stiffening a Blow to Cancer Cells
Researchers develop a way to predict how a tumor tissue's physical properties affect its response to chemotherapy drugs.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
New Strategy for Choosing Cancer Drugs
Device can predict tumor responses by measuring cell growth after drug exposure.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos